Medicine and Dentistry
Abdominal Cancer
8%
Adverse Event
7%
Cancer
8%
Cancer Incidence
8%
Cancer Registry
6%
Cancer Staging
5%
Clinical Guideline
16%
Clinical Oncology
16%
Clinical Trial
17%
Combination Therapy
16%
Comorbidity
6%
Conservative Treatment
8%
Contouring
16%
Coronary Artery
12%
Diseases
18%
Esophageal Cancer
37%
Esophageal Squamous Cell Carcinoma
100%
Hazard Ratio
15%
ICD-10
6%
Ipilimumab
40%
Kyphoplasty
8%
Lung
8%
Lung Cancer
16%
Malignant Neoplasm
18%
Mortality Rate
14%
Nivolumab
83%
Overall Survival
40%
Patient History of Chemotherapy
16%
Patient Preference
8%
Patient-Data
5%
Percutaneous Vertebroplasty
16%
Phase III and IV Trials
18%
Prevalence
6%
Programmed Death 1 Ligand 1
10%
Programmed Death-Ligand 1
12%
Progression Free Survival
11%
Radiation Therapy
16%
Relative Survival
16%
Sodium Fluoride
34%
Systematic Review
16%
Treatment Planning
16%
Tumor Cell
19%
Upper Gastrointestinal Cancer
22%
Volumetric Modulated Arc Therapy
12%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
8%
Adenocarcinoma
10%
Adverse Event
5%
Biological Marker
16%
Cancer Incidence
8%
Cancer Registry
6%
Cancer Staging
5%
Cetuximab
16%
Chemoradiation Therapy
18%
Chemotherapy
57%
Combination Therapy
16%
Comorbidity
6%
Digestive System Cancer
22%
Disease Specific Survival
11%
Esophageal Squamous Cell Carcinoma
74%
Esophagus Cancer
37%
Fluorouracil
6%
ICD-10
6%
Ipilimumab
39%
Lung Cancer
16%
Malignant Neoplasm
16%
microRNA
5%
microRNA 375
16%
Mortality Rate
14%
Neoplasm
18%
Nivolumab
50%
Overall Survival
29%
Oxaliplatin
5%
Phase III Trials
16%
Prevalence
6%
Programmed Death 1 Ligand 1
9%
Progression Free Survival
9%
Sodium Fluoride
34%
Immunology and Microbiology
Cetuximab
16%
Disease Specific Survival
16%
Esophagus
16%
Ipilimumab
40%
Nivolumab
66%
Overall Survival
48%
Prognostic Biomarker
16%
Programmed Death 1 Ligand 1
10%
Programmed Death-Ligand 1
9%
Progression Free Survival
11%
Squamous Cell
80%
Tumor Cell
19%
